Sign up

Montanova Capital, LLC

$4.8B assets · 95 holdings · Q2 2026 · Filed 14 AUG 2026

About Montanova Capital, LLC’s 13F portfolio

Montanova Capital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Montanova Capital, LLC reported $4.8B across 95 US-listed positions (). Its largest position is VERADERMICS INC (MANE) at 11% of the reported book, and its ten biggest holdings make up 45% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$4.8B
Assets (13F)
#842
of 8,845 by size
95
Holdings
45%
Top-10 weight
46
Buys
31
Sells
Top holdings · Q2 2026
95 total
#StockPrice% of portfolioSharesValue
1
NYSE: MANE
VERADERMICS INC
—
—
11%
4.2M$512.5M
2
NASDAQ: ARQT
ARCUTIS BIOTHERAPEUTICS INC
$27.17
−1.59%
6.9%
12.4M$326.1M
3
NASDAQ: LEGN
LEGEND BIOTECH CORP
$16.10
−0.92%
4.3%
7.1M$204.2M
4
NASDAQ: PVLA
PALVELLA THERAPEUTICS INC NE
$145.77
−0.55%
3.6%
1.1M$173.5M
5
NASDAQ: AVBP
ARRIVENT BIOPHARMA INC
$11.26
+3.30%
3.3%
4.5M$156.9M
6
NASDAQ: BNTC
BENITEC BIOPHARMA INC
$8.14
−1.57%
3.2%
11.5M$154.5M
7
NYSE: BHVN
BIOHAVEN LTD
$13.65
+5.81%
3.2%
10.3M$153.1M
8
NASDAQ: AMD
ADVANCED MICRO DEVICES INC
$489.19
−7.72%
3.1%
257K$149.4M
9
NYSE: RCUS
ARCUS BIOSCIENCES INC
$15.78
+0.13%
3.1%
4.8M$147.3M
10
NYSE: TSM
TAIWAN SEMICONDUCTOR MANUFAC
$352.09
−2.90%
3.1%
305K$145.5M
11
NASDAQ: NVDA
NVIDIA CORPORATION
$145.98
−3.30%
3.0%
721K$144.2M
12
NASDAQ: EYPT
EYEPOINT INC
$0.26
−2.87%
2.5%
8.3M$118.6M
13
NYSE: SYY
SYSCO CORP
$77.15
−0.99%
2.5%
1.4M$118.0M
14
NYSE: GE
GE AEROSPACE
$318.88
−2.81%
2.4%
310K$116.0M
15
NASDAQ: IMTX
IMMATICS N.V
$5.95
−2.46%
2.4%
11.2M$113.4M
16
NYSE: MGM
MGM RESORTS INTERNATIONAL
$33.41
−0.98%
2.3%
2.3M$111.2M
17
NASDAQ: META
META PLATFORMS INC
$596.22
−3.27%
2.1%
176K$99.0M
18
NASDAQ: CAPR
CAPRICOR THERAPEUTICS INC
$7.53
−6.23%
2.1%
4.1M$98.6M
19
NASDAQ: KURA
KURA ONCOLOGY INC
$7.35
+0.14%
2.0%
8.6M$94.1M
20
NASDAQ: GLUE
MONTE ROSA THERAPEUTICS INC
$8.91
−1.76%
1.8%
3.5M$85.9M
21
NASDAQ: AVLN
AVALYN PHARMACEUTICALS INC
—
—
1.7%
2.5M$82.4M
22
NYSE: HD
HOME DEPOT INC
$336.68
−0.28%
1.7%
226K$79.7M
23
NASDAQ: HUT
HUT 8 CORP
$55.80
−2.43%
1.6%
670K$77.3M
24
NYSE: COF
CAPITAL ONE FINL CORP
$181.76
−1.38%
1.4%
333K$66.8M
25
NYSE: VMC
VULCAN MATLS CO
$274.19
−1.98%
1.3%
215K$63.4M

Showing 1–25 of 95 positions on this page reported in this 13F.

Sector allocation
  • Healthcare51%
  • Technology11%
  • Consumer Cyclical6.0%
  • Financial Services4.9%
  • Industrials3.9%
  • Communication Services3.1%
  • Consumer Defensive2.5%
  • Basic Materials1.6%
Recent activity · vs 2026-03-31
Bought46
  • AddedARQTARCUTIS BIOTHERAPEUTICS INC+0.9%$326.1M
  • AddedAVBPARRIVENT BIOPHARMA INC+2.6%$156.9M
  • AddedTSMTAIWAN SEMICONDUCTOR MANUFAC+2.0%$145.5M
  • AddedNVDANVIDIA CORPORATION+25.4%$144.2M
  • AddedSYYSYSCO CORP+21.8%$118.0M
  • AddedMGMMGM RESORTS INTERNATIONAL+7.7%$111.2M
  • AddedMETAMETA PLATFORMS INC+3.6%$99.0M
  • AddedCAPRCAPRICOR THERAPEUTICS INC+7.2%$98.6M
  • NewAVLNAVALYN PHARMACEUTICALS INC—$82.4M
  • AddedHDHOME DEPOT INC+2.0%$79.7M
Sold31
  • ReducedLEGNLEGEND BIOTECH CORP−6.7%$204.2M
  • ReducedPVLAPALVELLA THERAPEUTICS INC NE−1.6%$173.5M
  • ReducedRCUSARCUS BIOSCIENCES INC−5.1%$147.3M
  • ReducedGLUEMONTE ROSA THERAPEUTICS INC−16.0%$85.9M
  • ReducedAMZNAMAZON COM INC−19.3%$48.8M
  • ReducedAPOAPOLLO GLOBAL MGMT INC−1.1%$45.3M
  • ReducedBACBANK OF AMER CORP−39.0%$45.0M
  • ReducedCMPXCOMPASS THERAPEUTICS INC−1.4%$30.9M
  • ReducedUNHUNITEDHEALTH GROUP INC−36.3%$26.7M
  • ReducedFULCFULCRUM THERAPEUTICS INC−43.9%$13.5M
5%+ Beneficial Ownership Stakes · 2 activist (13D) · 17 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
BNTC
Benitec Biopharma Inc.
13D44.1%17.8MFiled 10 NOV 2025
2
IFRX
InflaRx N.V.
13G15.6% · 2 classes22.9MFiled 14 AUG 2026
3
MOLN
MOLECULAR PARTNERS AG
13G10.6%4.3MFiled 02 MAY 2025
4
DBVT
DBV Technologies S.A.
13G9.9%15.2MFiled 11 APR 2025
5
ZURA
Zura Bio Limited
13G9.9% · 2 classes9.5MFiled 12 MAY 2026
6
AVBP
ArriVent BioPharma, Inc.
13G9.9%3.4MFiled 13 AUG 2025
7
FULC
Fulcrum Therapeutics, Inc.
13G9.4%5.1MFiled 02 MAY 2025
8
FTH
Faeth Therapeutics, Inc.
13G8.9%2.3MFiled 13 NOV 2026
9
MANE
Veradermics, Incorporated
13D8.8% · 2 classes3.7MFiled 21 AUG 2026
10
IMTX
Immatics N.V.
13G8.3% · 2 classes11.2MFiled 13 FEB 2026
11
CMPX
Compass Therapeutics, Inc.
13G8.2%14.1MFiled 21 AUG 2025
12
REPL
Replimune Group, Inc.
13G7.9%6.6MFiled 06 AUG 2026
13
BHVN
Biohaven Ltd.
13G7.8%10.3MFiled 13 FEB 2026
14
LXEO
Lexeo Therapeutics, Inc.
13G7.7%5.7MFiled 13 APR 2026
15
PVLA
Palvella Therapeutics, Inc.
13G7.4%822KFiled 13 NOV 2025
16
—
89bio, Inc.
13G5.6%8.3MFiled 13 NOV 2025
17
GLUE
Monte Rosa Therapeutics, Inc.
13G5.5%3.4MFiled 16 APR 2025
18
ABEO
Abeona Therapeutics Inc.
13G5.2%2.7MFiled 13 AUG 2025
19
ERAS
Erasca, Inc.
13G5.1%14.5MFiled 13 AUG 2025

Showing all 19 disclosed stakes. 8 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Montanova Capital, LLC’s 13F portfolio

Montanova Capital, LLC’s $4.8B 13F book is spread across 95 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 45%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are MANE, ARQT, LEGN, PVLA and AVBP, led by VERADERMICS INC (MANE) at 11% of the portfolio. The heaviest sector exposure is Healthcare (51%), then Technology (11%).

What Montanova Capital, LLC changed last quarter

Between 2026-03-31 and Q2 2026, Montanova Capital, LLC was a net buyer: it opened 21 new positions and added to 25 more, while trimming 17 and closing 14 outright. Against a 95-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ARCUTIS BIOTHERAPEUTICS INC (ARQT), and its biggest reduction was LEGEND BIOTECH CORP (LEGN).

What a 13F does and doesn’t reveal

A 13F captures only Montanova Capital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Montanova Capital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Montanova Capital, LLC's profile on this page is built directly from those filings.

How current is the 13F data on Montanova Capital, LLC's page?

It reflects Montanova Capital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Montanova Capital, LLC files its next quarterly report, this page refreshes automatically.

Can I see Montanova Capital, LLC's complete list of holdings?

This page highlights Montanova Capital, LLC's largest positions rather than all 95 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Montanova Capital, LLC's filings.

Does a 13F show everything Montanova Capital, LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Montanova Capital, LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Montanova Capital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.